Modulation of cerebral malaria by fasudil and other immune-modifying compounds

Experimental Parasitology

Volumn 125, Issue 2, 2010, Pages 141-146

  Waknine Grinberg, Judith H ^a   McQuillan, James A ^b   Hunt, Nicholas ^b   Ginsburg, Hagai ^a   Golenser, Jacob ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cerebral malaria; Curcumin; Fasudil; Immunomodulation; Plasmodium berghei ANKA

Indexed keywords

CURCUMIN; FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; PROTEIN KINASE INHIBITOR; RHO KINASE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; GERMFREE ANIMAL; INSTITUTE FOR CANCER RESEARCH MOUSE; MALARIA;

MURINAE; MUS; PLASMODIUM BERGHEI;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CURCUMIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; IMMUNOLOGIC FACTORS; MALARIA, CEREBRAL; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PARASITEMIA; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SPECIFIC PATHOGEN-FREE ORGANISMS; VASODILATOR AGENTS;

EID: 77951887094     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.01.005     Document Type: Article

References (59)

1. Barak V., Kalickman I., Halperin T., Birkenfeld S., Ginsburg I. PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. European Cytokine Network 2004, 15:203-209.
2. Beni S.M., Kohen R., Reiter R.J., Tan D.X., Shohami E. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NFkappaB and AP-1. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2004, 18:149-151.
3. 2+ release and modulate the cell cycle of Plasmodium falciparum malaria parasites. Journal of Pineal Research 2005, 39:224-230.
4. Brennan P., O'Neill L.A. Inhibition of nuclear factor kappaB by direct modification in whole cells - mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochemical Pharmacology 1998, 55:965-973.
5. Carman-Krzan M., Wise B.C. Arachidonic acid lipoxygenation may mediate interleukin-1 stimulation of nerve growth factor secretion in astroglial cultures. Journal of Neuroscience Research 1993, 34:225-232.
6. Charunwatthana P., Abul Faiz M., Ruangveerayut R., Maude R.J., Rahman M.R., Roberts L.J., Moore K., Bin Yunus E., Hoque M.G., Hasan M.U., Lee S.J., Pukrittayakamee S., Newton P.N., White N.J., Day N.P., Dondorp A.M. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. Critical Care Medicine 2009, 37:516-522.
7. Coltel N., Combes V., Hunt N.H., Grau G.E. Cerebral malaria - a neurovascular pathology with many riddles still to be solved. Current Neurovascular Research 2004, 1:91-110.
8. Combe B. Thalidomide: new indications?. Joint Bone Spine 2001, 68:582-587.
9. Cui L., Miao J., Cui L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrobial Agents and Chemotherapy 2007, 51:488-494.
10. Curfs J.H., Hermsen C.C., Meuwissen J.H., Eling W.M. Immunization against cerebral pathology in Plasmodium berghei-infected mice. Parasitology 1992, 105:7-14.
11. Curfs J.H., van der Meide P.H., Billiau A., Meuwissen J.H., Eling W.M. Plasmodium berghei: recombinant interferon-gamma and the development of parasitemia and cerebral lesions in malaria-infected mice. Experimental Parasitology 1993, 77:212-223.
12. Dhib-Jalbut S. Glatiramer acetate (copaxone) therapy for multiple sclerosis. Pharmacological Therapy 2003, 98:245-255.
13. Eckstein-Ludwig U., Webb R.J., van Goethem I.D.A., East J.M., Lee A.G., Kimura M., O'Neill P.M., Bray P.G., Ward S.A., Krishna S. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
14. Engwerda C., Belnoue E., Grüner A.C., Rénia L. Experimental models of cerebral malaria. Current Topics in Microbiology and Immunology 2005, 297:103-143.
15. Fride E., Shohami E. The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. Neuroreport 2002, 13:1833-1841.
16. Gallien S., Milea D., Thiebaut M.M., Bricaire F., Le Hoang P. Brain and optic nerve ischemia in malaria with immune disorders. Journal of Infection 2007, 54:e1-e3.
17. Gallily R., Breuer A., Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. European Journal of Pharmacology 2000, 406:R5-7.
18. Gao X., Kuo J., Jiang H., Deeb D., Liu Y., Divine G., Chapman R.A., Dulchavsky S.A., Gautam S.C. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochemical Pharmacology 2004, 68:51-61.
19. Golenser J., Waknine J.H., Krugliak M., Hunt N.H., Grau G.E. Current perspectives on the mechanism of action of artemisinins. International Journal of Parasitology 2006, 36:1427-1441.
20. Hunt N.H., Grau G.E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends in Immunology 2003, 249:491-499.
21. Idro R., Jenkins N.E., Newton C.R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurology 2005, 4:827-840.
22. Im J.Y., Han P.L. Nordihydroguaiaretic acid induces astroglial death via glutathione depletion. Journal of Neuroscience Research 2007, 85:3127-3134.
23. Jeon K.S., Na H.J., Kim Y.M., Kwon H.J. Antiangiogenic activity of 4-O-methylgallic acid from Canavalia gladiata, a dietary legume. Biochemical and Biophysical Research Communications 2005, 330:1268-1274.
24. Kim S.Y., Kim T.B., Moon K.A., Kim T.J., Shin D., Cho Y.S., Moon H.B., Lee K.Y. Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo. Experimental and Molecular Medicine 2008, 40:461-476.
25. Lackner P., Part A., Burger C., Dietmann A., Broessner G., Helbok R., Reindl M., Schmutzhard E., Beer R. Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Malaria Journal 2009, 8:36-46.
26. Li C., Seixas E., Langhorne J. Rodent malarias: the mouse as a model for understanding immune responses and pathology induced by the erythrocytic stages of the parasite. Medical Microbiology and Immunology 2001, 189:115-126.
27. Maitland K., Newton C.R. Acidosis of severe falciparum malaria: heading for a shock?. Trends in Parasitology 2005, 21:11-16.
28. Martinelli A., Rodrigues L.A., Cravo P. Plasmodium chabaudi: efficacy of artemisinin + curcumin combination treatment on a clone selected for artemisinin resistance in mice. Experimental Parasitology 2008, 119:304-307.
29. Martins Y.C., Smith M.J., Pelajo-Machado M., Werneck G.L., Lenzi H.L., Daniel-Ribeiro C.T., Carvalho L.J. Characterization of cerebral malaria in the outbred Swiss Webster mouse infected by Plasmodium berghei ANKA. International Journal of Experimental Pathology 2009, 90:119-130.
30. Masumoto N., Tanabe Y., Saito M., Nakayama K. Attenuation of pressure-induced myogenic contraction and tyrosine phosphorylation by fasudil, a cerebral vasodilator, in rat cerebral artery. British Journal of Pharmacology 2000, 130:219-230.
31. Mishra S.K., Wiese L. Advances in the management of cerebral malaria in adults. Current Opinion in Neurology 2009, 22:302-307.
32. Moeslinger T., Friedl R., Volf I., Brunner M., Koller E., Spieckermann P.G. Inhibition of inducible nitric oxide synthesis by the herbal preparation PADMA 28 in macrophage cell line. Canadian Journal of Physiology and Pharmacology 2000, 78:861-866.
33. Muniz-Junqueira M.I., Silva F.O., Paula-Junior M.R., Tosta C.E. Thalidomide influences the function of macrophages and increases the survival of Plasmodium berghei-infected CBA mice. Acta Tropica 2005, 94:128-138.
34. Nandakumar D.N., Nagaraj V.A., Vathsala P.G., Rangarajan P., Padmanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrobial Agents and Chemotherapy 2006, 50:1859-1860.
35. Neill A.L., Hunt N.H. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology 1992, 105:165-175.
36. Neurauter G., Wirleitner B., Schroecksnadel K., Schennach H., Ueberall F., Fuchs D. PADMA 28 modulates interferon-gamma-induced tryptophan degradation and neopterin production in human PBMC in vitro. International Immunopharmacology 2004, 4:833-839.
37. Newton C.R., Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacology and Therapeutics 1998, 79:1-53.
38. Newton C.R., Warrell D.A. Neurological manifestations of falciparum malaria. Annals of Neurology 1998, 43:695-702.
39. Offen D., Gilgun-Sherki Y., Barhum Y., Benhar M., Grinberg L., Reich R., Melamed E., Atlas D. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. Journal of Neurochemistry 2004, 89:1241-1251.
40. Pan M.H., Lin-Shiau S.Y., Lin J.K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochemical Pharmacology 2000, 60:1665-1676.
41. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
42. Penet M.F., Viola A., Confort-Gouny S., Le Fur Y., Duhamel G., Kober F., Ibarrola D., Izquierdo M., Coltel N., Gharib B., Grau G.E., Cozzone P.J. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. Journal of Neuroscience 2005, 25:7352-7358.
43. Randall L.M., Amante F.H., Zhou Y., Stanley A.C., Haque A., Rivera F., Pfeffer K., Scheu S., Hill G.R., Tamada K., Engwerda C.R. Cutting edge: selective blockade of LIGHT-lymphotoxin beta receptor signaling protects mice from experimental cerebral malaria caused by Plasmodium berghei ANKA. Journal of Immunology 2008, 181:7458-7462.
44. Reddy R.C., Vatsala P.G., Keshamouni V.G., Padmanaban G., Rangarajan P.N. Curcumin for malaria therapy. Biochemical and Biophysical Research Communications 2005, 326:472-474.
45. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
46. Sanni L.A., Rae C., Maitland A., Stocker R., Hunt N.H. Is Ischemia involved in the pathogenesis of murine cerebral malaria?. American Journal of Pathology 2001, 159:1105-1112.
47. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., Asano T. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Japanese Journal of Pharmacology 1999, 80:41-48.
48. Shibuya M., Hirai S., Seto M., Satoh S., Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. Journal of the Neurological Sciences 2005, 238:31-39.
49. Shoemaker J.P., McAllister R.G., Selby J.B., Hoffman R.V. Effect of hypothyroidism on parasitemia and survival in rodent malaria. American Journal of Medical Science 1974, 268:281-285.
50. Singh N., Misra K. Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs. Bioinformation 2009, 3:255-262.
51. Sun X., Minohara M., Kikuchi H., Ishizu T., Tanaka M., Piao H., Osoegawa M., Ohyagi Y., Shimokawa H., Kira J. The selective Rho-kinase inhibitor fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2006, 180:126-134.
52. Taoufiq Z., Gay F., Balvanyos J., Ciceron L., Tefit M., Lechat P., Mazier D. Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. Journal of Infectious Diseases 2008, 197:1062-1073.
53. Treeprasertsuk S., Krudsood S., Tosukhowong T., Maek-A-Nantawat W., Vannaphan S., Saengnetswang T., Looareesuwan S., Kuhn W.F., Brittenham G., Carroll J. N-acetylcysteine in severe falciparum malaria in Thailand. Southeast Asian Journal of Tropical Medical Public Health 2003, 34:37-42.
54. Wade D.T., Robson P., House H., Makela P., Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003, 17:21-29.
55. Watt G., Jongsakul K., Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM: Monthly Journal of the Association of Physicians 2002, 95:285-290.
56. WHO: Liaison bulletin of the malaria programme WHO/AFRO, 2000. (accessed 17.08.09). http://www.afro.who.int/press/periodicals/malaria/jan2000.pdf.
57. Yamaguchi H., Kasa M., Amano M., Kaibuchi K., Hakoshima T. Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 2006, 14:589-600.
58. Yamashita K., Kotani Y., Nakajima Y., Shimazawa M., Yoshimura S., Nakashima S., Iwama T., Hara H. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Research 2007, 1154:215-224.
59. Yan Y., Inuo G., Akao N., Tsukidate S., Fujita K. Down-regulation of murine susceptibility to cerebral malaria by inoculation with third-stage larvae of the filarial nematode Brugia pahangi. Parasitology 1997, 114:333-338.